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Purpose: The clinical efﬁcacy of cancer peptide vaccine therapy is insufﬁcient. To enhance the anti-tumor
effect of peptide vaccine therapy, we combined this therapy with an anti-CD4 mAb (GK1.5), which is
known to deplete CD4þ cells, including regulatory T cells (Tregs).
Methods: To determine the treatment schedule, the number of lymphocyte subsets in the peripheral
blood of mice was traced by ﬂow cytometry after administration of anti-CD4 mAb. The ovalbumin
(OVA)257–264 peptide vaccine was injected intradermally and anti-CD4 mAb was administered in-
traperitoneally into C57BL/6 mice at different schedules. We evaluated the enhancement of OVA peptide-
speciﬁc cytotoxic T lymphocyte (CTL) induction in the combination therapy using the ELISPOT assay,
CD107a assay, and cytokine assay. We then examined the in vivo metastasis inhibitory effect by OVA
peptide vaccine therapy in combination with anti-CD4 mAb against OVA-expressing thymoma (EG7) in a
murine liver metastatic model.
Results: We showed that peptide-speciﬁc CTL induction was enhanced by the peptide vaccine in com-
bination with anti-CD4 mAb and that the optimized treatment schedule had the strongest induction
effect of peptide-speciﬁc CTLs using an IFN-γ ELISPOT assay. We also conﬁrmed that the CD107aþ cells
secreted perforin and granzyme B and the amount of IL-2 and TNF produced by these CTLs increased
when the peptide vaccine was combined with anti-CD4 mAb. Furthermore, metastasis was inhibited by
peptide vaccines in combination with anti-CD4 mAb compared to peptide vaccine alone in a murine liver
metastatic model.
Conclusion: The use of anti-CD4 mAb in combination with the OVA peptide vaccine therapy increased the
number of peptide-speciﬁc CTLs and showed a higher therapeutic effect against OVA-expressing tumors.
The combination with anti-CD4 mAb may provide a new cancer vaccine strategy.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer peptide vaccine therapy can be used to prolong survivalB.V. This is an open access article u
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ura).while maintaining the quality of life (QOL) of patients and is ex-
pected to prevent recurrence. We previously reported that glypican-
3 (GPC3) was a cancer speciﬁc antigen [1–3] and identiﬁed GPC3-
derived peptides capable of inducing peptide-speciﬁc cytotoxic T
cells (CTLs) [4–6]. A variety of clinical trials of GPC3 peptide vaccine
therapy have been performed in hepatocellular carcinoma (HCC)
[7–9] and ovarian clear cell carcinoma [10]. We conﬁrmed the safety
and immunological efﬁcacy of the vaccine and showed the potential
to induce a clinical effect in some patients [7,8,10]. However, the
clinical efﬁcacy of cancer peptide vaccine therapy remains in-
sufﬁcient. Therefore, we are attempting to develop effective en-
hancement methods for peptide vaccine therapy such as in-
tratumoral peptide injection [11] and combination therapy with ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(alphaPD-1 Ab) [12]. Moreover, we believe that it is necessary to
develop potent enhancement methods for peptide vaccine therapy.
Several groups have suggested that depletion of CD4þ cells re-
sults in strong antitumor effects in tumor-bearing mouse models
because of the enhancement of CTL responses. den Boer et al. re-
ported that depletion of CD4þ cells results remarkably increased
the number and systemic spread of tumor-speciﬁc CD8þ T cells as
well as tumor eradication and enhanced survival [13]. Chamoto
et al. indicated that combination treatment of carcinoma-bearing
mice with regulatory T cell (Treg)-depletion therapy and a Treg-
recovery blockade using anti-CD25 monoclonal antibody (mAb) and
anti-transforming growth factor-β (anti-TGF-β) mAb was an efﬁ-
cient strategy for inducing strong antitumor immunity and com-
plete rejection of the tumor [14]. Ueha et al. determined that
combination treatment with anti-CD4 mAb and immune check-
point mAbs, particularly anti-PD-1 or anti-PD-L1 mAbs, synergisti-
cally suppressed tumor growth and greatly prolonged survival [15].
To enhance the anti-tumor effect of peptide vaccine therapy,
we included an anti-CD4 mAb (GK1.5). First, we tracked the
changes in the number of each lymphocyte subset in mice per-
ipheral blood by ﬂow cytometry after administration of anti-CD4
mAb in order to determine the best treatment schedule. The en-
hancement of ovalbumin (OVA) peptide-speciﬁc cytotoxic T lym-
phocyte (CTL) induction in the combination therapy was con-
ﬁrmed using an interferon-γ (IFN-γ) enzyme-linked immunospot
assay (ELISPOT assay), CD107a assay, and cytokine assay. Finally,
using a murine liver metastatic model, we observed the burden of
metastasis was suppressed by the peptide vaccines in combination
with anti-CD4 mAb.2. Materials and method
2.1. Mice
C57BL/6 mice were purchased from Charles River Laboratories Ja-
pan (Yokohama, Japan). Mice were maintained under the institutional
guidelines set by the Animal Research committee of the National
Cancer Center Hospital East. Mice were housed under speciﬁc-pa-
thogen-free conditions with a 12-h light cycle and food and water ad
libitum. Six-to-eight-week-old mice were used in all experiments.
2.2. Cell line
RMA-S cell lines, which have H2-Kb and -Db as major histo-
compatibility complex (MHC) class I epitopes, were maintained in
our laboratory. RMA-S is an antigen processing-defective cell line;
the cells cannot present endogenous antigens with MHC class I
epitopes [16]. EL4 and EG7 were maintained in our laboratory. EG7
expresses OVA protein as a model tumor antigen because the full-
length OVA gene had been transformed into EL4. EL4 was used as a
control target of EG7. B16 and MO4 were provided by the Cell
Resource Center for Biomedical Research Institute of Development,
Aging, and Cancer Tohoku University (Sendai, Japan). MO4 ex-
pressed OVA protein as a model tumor antigen. B16 was used as a
control target of MO4. These cells were maintained in vitro in RPMI
1640 supplemented with 10% fetal bovine serum.
2.3. Murine blood sampling
From the tip of the tail vein, 100 mL peripheral blood was collected.
The samples were analyzed using a ﬂow cytometer after hemolysis.2.4. Monoclonal antibodies and chemical reagents
The following mAbs were purchased from BioLegend (San
Diego, CA, USA): ﬂuorescein isothiocyanate (FITC)-conjugated Ar-
menian hamster anti-mouse CD3εmAb (145-2C11), phycoerythrin
(PE)-labeled rat anti-mouse CD8α mAb (53-6.7), PE/Cy7-labeled
rat anti-mouse CD4 mAb (RM4-5), APC-labeled rat anti-mouse
CD25 mAb (3C7), APC-labeled rat anti-mouse CD107a (LAMP-1)
mAb (1D4B), APC-labeled rat IgG2a, κ isotype control, APC-labeled
rat IgG2b, κ isotype control, APC/Cy7-labeled rat anti-mouse CD45
mAb (30-F11), and PE anti-mouse/rat/human forkhead box P3
(FOXP3) ﬂow kit. Additionally, V500 Rat anti-Mouse CD44 mAb
(IM7) and V450 Rat anti-mouse CD62L mAb (MEL-14) were pur-
chased from BD Biosciences (Franklin Lakes, NJ, USA). 7-amino-
actinomycin D (7-AAD) viability dye was purchased from Beckman
Coulter Inc., (Brea, CA, USA). FcR blocking reagent, mouse, was
purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).
2.5. Flow Cytometry (FCM)
The FCM data were acquired using the FACSCanto II system (BD
Biosciences) and analyzed using the Flow-Jo software (Tree Star,
Ashland, OR, USA).
2.6. Administration of monoclonal antibody
GK1.5, a rat anti mouse CD4 mAb and LTF-2, a rat isotype
control IgG2b were purchased from Bio X Cell. Mice received in-
traperitoneal injection of 5 mg/kg GK1.5 or LTF-2 as the isotype
control on day 0.
2.7. Detection of CD4þ CD25þ FOXP3þ cells after administration of
anti-CD4 mAb in EG7-bearing mice
EG7 was implanted subcutaneously in the right ﬂank of mice.
Anti-CD4 mAb was administered intraperitoneally into the EG7-
bearing mice. The mice were analyzed using ﬂow cytometry on
day 1 after administration of anti-CD4 mAb. PE anti-mouse/rat/
human FOXP3 Flow Kit was used for FOXP3 intracellular staining
according to the manufacturer’s instructions.
2.8. Peptide vaccine
H-2Kb-restricted OVA257–264 (SIINFEKL) was purchased from
AnaSpec, Inc. (Fremont, CA, USA). OVA peptide vaccine consisted of
peptide:7% NaHCO3:incomplete Freund's adjuvant (IFA)¼1:9:10.
Mice were injected intradermally at the base of the tail with the
OVA peptide vaccine.
2.9. IFN-γ ELISPOT assay
Effector cells were cocultured with each cancer cell line as a
target cell at the indicated effector/target (E/T) ratio. AN IFN-g
ELISPOT assay was carried out as previously described [17].
2.10. CD107a assay
Effector cells were isolated using mouse CD8 microbeads
(Miltenyi Biotec) from peripheral blood. The CD8þ cells were in-
cubated with cancer cell lines for 3.5 h at 37 °C. APC-conjugated
CD107a mAb or isotype control rat IgG2a mAb were incubated in
the mixture during the incubation period; after incubation, the
cells were stained with additional PE-conjugated anti-CD8 mAb,
FITC-conjugated anti-CD3εmAb, and 7-AAD Viability Dye and
analyzed using FACSCanto II system and Flow-Jo software.
Fig. 1. Number of lymphocyte subsets after administration of anti-CD4 mAb. (A) Representative ﬂow cytometry proﬁles of CD4þ T cells in peripheral blood on days 0, 1, and
24 after administration of anti-CD4 mAb. (B) Changes in CD4þ T cell counts in the peripheral blood after administration of anti-CD4 mAb (GK1.5) (n¼3). (C) Changes in CD8þ
T cell counts in peripheral blood after administration of anti-CD4 mAb (GK1.5) (n¼3). (D) Representative ﬂow cytometry proﬁles of CD4þ CD25þ FOXP3þ cells in sple-
nocytes of EG7-bearing mice on day 1 after administration of anti-CD4 mAb. (E) Statistical analysis of (D) (n¼3).**Po0.01, differences are statistically signiﬁcant between the
two values.
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Supernatants of the IFN-γ ELISPOT assay and CD107a assay were
collected and interleukine-2 (IL-2) and tumor necrosis factor (TNF)
were measured using a Cytometric Bead Array (BD Bioscience) ac-
cording to the manufacturer's instructions. Samples were analyzed
using a FACSCanto II system and the FCAP Array Software 3.0 (BD
Bioscience).
2.12. Murine liver metastatic model
A mouse model of liver metastasis was developed by injecting
tumor cells into the spleen. We obtained viable single-cell sus-
pensions of subcutaneous tumor cells using a gentleMACS Octo
Dissociator with Heaters (Miltenyi Biotec). The single-cell sus-
pensions were injected into the spleen. Mice were anesthetized
using isoﬂurane vaporizer. A small incision was made in the left
ﬂank to reveal the spleen. A total of 1106 cells/100 mL of EG7 was
injected into the spleen using a 27-gauge needle and the incision
was stapled. The spleen weight and the major axis of splenic tu-
mors were estimated as indicators of splenic tumors. The liver
weight was estimated as an indicator of hepatic tumors because
the number of metastases in the liver could not be counted.
2.13. Immunohistochemical analysis
Immunohistochemical analysis of frozen tissue sections was
done as described previously [18] using mAb speciﬁc to CD4 (L3T4;
BD Pharmingen, San Diego, CA) or CD8(53-6.7; BD Pharmingen).
Stained samples were subjected to microscopic analysis on a mi-
croscope (EX51 Olympus, Tokyo, Japan).
2.14. Statistical analysis
All data are presented as the mean7SD. Student's t test for
comparison of means was used to compare groups. P values less
than 0.05 were considered to be statistically signiﬁcant.3. Results
3.1. Changes in the number of each lymphocyte subset after anti-CD4
mAb administration
To determine the treatment schedule, the number of each
lymphocyte subset in the peripheral blood of mice was traced after
administration of anti-CD4 mAb using ﬂow cytometry. The subsets
of CD4þ T cells were evaluated on day 0, 1, and 24 (Fig. 1A). CD4þ
T cell counts were dramatically reduced in mice peripheral blood
by the ﬁrst day after anti-CD4 mAb administration (Fig. 1A and B).
Subsequently, CD4þ T cell count gradually increased, recovering to
50% at 24 days after anti-CD4 mAb administration (Fig. 1B). In
contrast, CD8þ T cell number did not change after anti-CD4 mAb
administration (Fig. 1C). We determined that CD4þ CD25þ
FOXP3þ cells disappeared in the splenocytes of EG7-bearing mice
on day 1 after anti-CD4 mAb administration. The number of CD4þ
CD25þ FOXP3þ cells in spleen of EG7-bearing mice on day 1 after
administration of anti-CD4 mAb signiﬁcantly decreased compared
with the untreated group. As CD4þ T cells, including Tregs, had
nearly disappeared, we administered the OVA peptide vaccine one
day after anti-CD4 mAb administration (Fig. 1D and E).
3.2. Effect of peptide vaccine therapy was enhanced in combination
with anti-CD4 mAb
To evaluate the enhancement of OVA peptide-speciﬁc CTLinduction in the combination therapy, we compared with the
schedule I of OVA peptide vaccine alone, the schedule II of com-
bination treatment starting from anti-CD4 mAb administration,
and the schedule III of combination treatment starting from OVA
peptide vaccination using the IFN-γ ELISPOT assay (Fig. 2A). We
then determined that the increase in OVA-speciﬁc CTL induction
by OVA peptide vaccine in combination with anti-CD4 mAb was
higher than that obtained using OVA peptide vaccine alone (Fig. 2B
and C). Next, we compared the two combination schedules with
anti-CD4 mAb and OVA peptide vaccine (schedules II and III). OVA-
speciﬁc CTL induction by schedules II and III showed no signiﬁcant
differences. But the mean value of spot number in schedules III
was higher than that of spot number in schedules II. From this, we
decided to adopt schedules III in subsequent experiments.
3.3. Multi-functionality of peptide-speciﬁc CTLs induced by peptide
vaccine therapy in combination with anti-CD4 mAb
To determine the multi-function of peptide-speciﬁc CTL by
combination therapy, we performed a CD107a assay on day 13 and
IFN-γ ELISPOT assay on day14 after priming of the OVA peptide
vaccine using schedule III of Fig. 2A (Fig. 3A). Perforin and granzyme
secretion from CD107aþ cells increased and the production of IL-2
and TNF from these CTLs increased following combined treatment
with anti-CD4 mAb and OVA peptide vaccines (Fig. 3B and D). The
phenotype of these CD8þ CD107aþ cells were CD44 high CD62L
low effector/memory and that of CD8þ CD107a- cells were included
in naïve, central/memory, effector/memory (Fig. 3C). The increase in
OVA-speciﬁc CTL induction by OVA peptide vaccine in combination
with anti-CD4 mAb was detected using an IFN-γ ELISPOT assay, and
the production of IL-2 and TNF from these CTLs was detected in the
combination schedule (Fig. 3E and F). The results of the IFN-γ ELI-
SPOT assay, CD107a upregulation assay, and cytokine assay in-
dicated that the depletion of CD4þ T cells enhanced the function of
CD8þ T cells in the murine peripheral blood and spleen.
3.4. Metastasis was inhibited by peptide vaccine therapy in combi-
nation with anti-CD4 mAb
We evaluated whether the number of metastasis was sup-
pressed by the peptide vaccines in combination with anti-CD4 mAb
in the murine liver metastatic model. The treatments of schedule III
(Fig. 2A) were performed before and after tumor implantation
(Fig. 4A). The spleen weight and liver weight of the combination
group were signiﬁcantly lighter than those of the untreated group
and group of OVA peptide alone. However, the spleen weight and
liver weight of the combination group showed no signiﬁcant dif-
ference from those in the group treated with anti-CD4 mAb alone.
The major axis of splenic tumors following combination therapy
was signiﬁcantly shorter than that for the other groups (Fig. 4C).
3.5. The increase of the inﬁltration of CD8þ CTL into the liver me-
tastasis and the decrease of CD4þT cells in the liver after the ad-
ministration of anti-CD4 mAb
CD8þ T cells inﬁltration in the liver metastatic tumors was
higher in the combination therapy group than in OVA peptide
vaccine alone and untreated group (Fig. 5A). We could not evaluate
CD4þ T cells inﬁltration into the liver metastatic tumors, because
EG7 cells were expressing CD4 on the cell surfaces in vivo un-
expectedly. But CD4þ T cells inﬁltration in liver surrounding EG7
tumor was fewer in anti-CD4 mAb treatment group (anti-CD4
mAb alone, combination OVA peptide vaccine and anti-CD4 mAb)
than in no anti-CD4 mAb treatment group (no treatment, OVA
peptide vaccine alone) (Fig. 5B).
Fig. 2. Comparison of peptide-speciﬁc CTL induction by peptide vaccine therapy in combination with anti-CD4 mAb. (A) Schedules for IFN-γ ELISPOT assay. I: OVA peptide
vaccine alone, II: Starting from anti-CD4 mAb, and two administrations of OVA peptide vaccine, III: Starting from OVA peptide vaccine, and OVA peptide vaccination after anti-
CD4 mAb administration (OVAp: OVA peptide vaccine, αCD4: anti-CD4 mAb). (B) Representative results of IFN-γ ELISPOT assay are shown. Effector cells: CD8þ spleen cells.
Groups: I, II, III. Target cells: RMA-S cells, OVA peptide-pulsed RMA-S cells, EL4 cells, EG7 cells. Effector/target ratio¼10. (C) Statistical analysis of (B). Comparisons of spot
numbers between the group of OVA peptide alone (I) and groups of combination treatment (II or III) [left]. Comparisons of spot numbers between two groups of combination
treatment (II and III) [right] (n¼3).*Po0.05,**Po0.01, differences are statistically signiﬁcant between the two value. ns, difference was not signiﬁcant between the two values.
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Fig. 3. Multi-function of peptide-speciﬁc CTL by peptide vaccine therapy in combination with anti-CD4 mAb. Representative data are shown. (A) Schedule for IFN-γ ELISPOT
assay and CD107a assay. On days 0 and 7, mice were injected intradermally at the base of the tail with OVA peptide vaccine. On day 6, mice were injected i.p. with anti-CD4
mAb. On day 13, the CD107a assay was conducted. On day 14, the IFN-γ ELISPOT assay was conducted. (B) CD107a assay of peripheral blood cells. Effector cells: CD8þ
peripheral blood cells. Groups: no treatment group, OVA peptide vaccine alone group, anti-CD4 mAb alone group, combination OVA peptide vaccine and anti-CD4 mAb
group. Target cells: RMA-S cells, OVA peptide pulsed RMA-S cells. (C) The ﬂow cytometric analysis of effector/memory phenotype of CD107aþ cells and CD107a- cells in
CD8þ T cells. (D) cytokine assay of peripheral blood cells. (E) IFN-γ ELISPOT assay and (F) cytokine assay of splenocytes. Effector cells: CD8þ spleen cells. Groups: no
treatment group, OVA peptide vaccine alone group, anti-CD4 mAb alone group, combination OVA peptide vaccine and anti-CD4 mAb group. Target cells: RMA-S cells, OVA
peptide pulsed RMA-S cells. Effector/target ratio¼2.
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Fig. 4. Suppression of tumor growth in the metastatic tumor model. The protocol for liver metastasis model was indicated in (A). All mice spleens were injected into with
1106 EG7 cells on day 0. On day 14, 7, 0, and 6, mice were injected intradermally at the base of the tail with the OVA peptide vaccine. On days 8 and 6, mice were
injected i.p. with anti-CD4 mAb. On day 14, the mice were sacriﬁced and liver weight, spleen weight, and the major axis of splenic tumor were measured. (B) Representative
liver metastasis and splenic tumor in each group. Groups: No treatment group, OVA peptide vaccine alone group, anti-CD4 mAb alone group, combination OVA peptide
vaccine and anti-CD4 mAb group (n¼5). (C) Statistical analysis of (B). Columns, mean number of liver weight, spleen weight, and major axis of splenic tumor.*Po0.05,
**Po0.01, differences were statistically signiﬁcant between the two values. ns, differences were not signiﬁcant between the two values.
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Fig. 5. Immunohistochemical analysis in murine liver. (A) The CD8þ T cells (brown color) inﬁltration into EG7 tumor in mice (no treatment, OVA peptide vaccine alone, and
combination OVA peptide vaccine and anti-CD4 mAb) after the administration of anti-CD4 mAb. (B) CD4þ T cells (brown color) inﬁltration in liver surrounding EG7 tumor in
no anti-CD4 mAb treatment group (no treatment, OVA peptide vaccine alone) and in anti-CD4 mAb treatment group (anti-CD4 mAb alone, combination OVA peptide vaccine
and anti-CD4 mAb).
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The aim of this study was to enhance the anti-tumor effect of
peptide vaccine therapy by combination with anti-CD4 mAb in a
mouse model. In this study, we examined the enhancement of the
metastasis inhibitory effect resulting from the use of peptide
vaccines in combination with anti-CD4 mAb in a murine liver
metastatic model. In this model, CD4þ cells, including Tregs, in-
terfere with CTL induction or its inﬁltration into the tumor.
Ueha et al. found that anti-CD4 mAb treatment enhanced an-
titumor CD8þ T cell responses and induced a shift toward type I
immunity within the tumor [15]. The immune response is regu-
lated by the Th1/Th2 cytokine balance [19,20]. Nagai et al. sug-
gested that the depletion of CD4þ T cells may result in elimination
of Th2 cells despite the abrogation of Th1 cells and induce further
activation of CD8þ T cells [21]. We also found that IFN-γ-induced
OVA-speciﬁc CTL induction increased in the spleen by OVA peptide
vaccine in combination with anti-CD4 mAb based on an IFN-γ
ELISPOT assay; the production of IL-2 and TNF from these CTLs in
the peripheral blood and spleen following the combination ther-
apy were determined using a cytokine assay (Fig. 3C). The deple-
tion of CD4þ T cells induced a shift toward type I immunity in the
peripheral blood and spleen, which led to enhancement of the
metastasis inhibitory effect by the activation of CD8þ T cells fol-
lowing combination therapy.
Filipazzi et al. reported that the activation of helper CD4þ T
cells was necessary for the induction of killer CD8þ T cells [22,23].
Based on the results of the previous study, it was not clear whe-
ther helper CD4þ T cells were required for tumor immunity.
However, CD4þ T cells may be required for the priming of peptide
vaccines, as the frequency of IFN-γ-induced peptide-speciﬁc CTLs
increased in the murine spleen for schedule III to a greater extent
than that in the case of schedule II administered with anti-CD4
mAb (Fig. 2C). Additional studies are required to conﬁrm this.
The efﬁcacy of immunotherapy in mouse models depends on
the tumor type. EG7 cells used in this study express CD4 on the
cell surface in vivo, but not in vitro [24]. However, at the beginning
of this study, EG7 cells in vivo were found to express CD4 on the
cell surface, as shown by immunohistochemical staining of CD4
(data not shown). The anti-CD4 mAb (GK1.5) directly killed EG7
cells in vivo through complement-dependent cytotoxicity [25],
which was considered to be inﬂuenced by the result of the murine
liver metastatic model. However, we observed metastasis sup-
pression effects following combination therapy in the mouse
model using CD4-negative OVA-expressing B16 melanoma, MO4
cells (data not shown). Other tumor cells should be tested in future
studies.
In this study, we used OVA as a model antigen, as OVA is
thought to be highly immunogenic compared to cancer antigens.
We are currently examining targeted cancer antigens such as GPC3
before conducting clinical trials involving combination therapy of
the peptide vaccine and anti-CD4 mAb.
The depletion of CD4þ cells may have adverse effects. No ser-
ious adverse effects were detected in our mouse model. In addi-
tion, no severe adverse effects were observed during phase II
clinical trials for T-cell malignancy with long-term administration
of humanized anti-CD4 mAbs [26,27]. Autoimmune diseases may
occur as result of the continuous reduction of CD4þ cells. How-
ever, the depletion of CD4þ cells in this study was transient, not
continuous. Although this change was transient, the risk of in-
fectious diseases was increased. Therefore, careful observation of
patients after administration of anti-CD4 mAb is required in clin-
ical trials.
Surgery and radiation therapy show excellent local control of
tumors, but they are inferior to chemotherapy and im-
munotherapy for systemic control. In particular, althoughextremely high-quality radiation therapy such as intensity-
modulated radiation therapy or ion radiotherapy has been
achieved, radiation enhances metastases under conditions of non-
curative doses [28]. Our strategy can suppress the progression of
cancer in combination with surgery or radiation therapy to sys-
temically control cancer metastasis and recurrence.
In conclusion, we demonstrated the enhancement of metastasis
inhibitory effects following administration of peptide vaccines in
combination with anti-CD4 mAb in a murine liver metastatic
model. Our results will contribute to the development of cancer
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